Bionomics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
Bionomics Stock Forecast and Price Target
Based on the current earnings figures, this year's price targets for Bionomics were recently set by distinguished experts, with an average mark of $12.25. If it reached this goal, it would represent a potential upside of approximately 1246.15% from the previous closing price in May, 2024. The high end is $27.54, and the low is $6.12. If you are not interested in BNOX stock, you may be interested in its competitors.
1246.15% Upside
Bionomics Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Bionomics's Price has increased by 100.00%, going from $0.00 to $0.00. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach $0.92 – an increase of 100.00%. The Bionomics forecast is for Fair Value to reach $1.58 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CSL Stock Forecast | CSL | Outperform |
12
|
$274.49 | Buy/Sell | $205.51 | -25.99% |
| TLX Stock Forecast | Telix Pharmaceuticals | Buy |
6
|
$14.67 | Buy/Sell | $13.37 | -1.16% |
| NEU Stock Forecast | Neuren Pharmaceuticals | Buy |
11
|
$19.06 | Buy/Sell | $26.43 | 39.45% |
| PNV Stock Forecast | PolyNovo | Outperform |
8
|
$2.01 | Buy/Sell | $1.88 | 6.47% |
| CUV Stock Forecast | Clinuvel Pharmaceuticals | Buy |
16
|
$15.06 | Buy/Sell | $27.41 | 47.74% |
Bionomics Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Bionomics's Revenue has gone down from $8.56M to $650.00k – a 92.41% drop. In the next year, analysts are expecting an increase in Revenue, predicting it will reach $8.70M – an increase of 1238.46%. The Bionomics forecast is for Revenue to reach $14.91M or grow by 2194.15%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IMU Stock Forecast | Imugene | Buy |
4
|
$0.08 | Buy/Sell | $0.35 | 425.00% |
| IMM Stock Forecast | Immutep | Buy |
8
|
$0.42 | Buy/Sell | $1.26 | 138.10% |
| OPT Stock Forecast | Opthea | Underperform |
10
|
$0.62 | Buy/Sell | $1.15 | 12.90% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MSB Stock Forecast | Mesoblast | Buy |
9
|
$1.10 | Buy/Sell | $0.69 | 0.00% |
| PYC Stock Forecast | PYC Therapeutics | Buy |
8
|
$0.10 | Buy/Sell | $0.30 | 260.00% |
| CGS Stock Forecast | Cogstate | Buy |
11
|
$1.40 | Buy/Sell | $1.85 | 28.57% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BOT Stock Forecast | Botanix Pharmaceuticals | - |
0
|
$0.19 | Buy/Sell | $0.00 | -100.00% |
| DXB Stock Forecast | Dimerix |
0
|
$0.32 | Buy/Sell | $0.00 | 81.25% | |
| ACW Stock Forecast | Actinogen Medical |
5
|
$0.04 | Buy/Sell | $0.15 | -100.00% |
Bionomics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Bionomics's EBITDA has grown, increasing from $-300.00k to $-26.83M – a growth of 8843.33%. The next year looks promising for Bionomics, with analysts predicting EBITDA of $-35.80M – an increase of 33.43%. Over the next seven years, experts anticipate that Bionomics's EBITDA will grow at a rate of 42.38%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BIT Stock Forecast | Biotron | - |
0
|
$0.06 | Buy/Sell | $0.00 | -100.00% |
| SPL Stock Forecast | Starpharma Holdings | - |
8
|
$0.12 | Buy/Sell | $0.95 | -100.00% |
| IVX Stock Forecast | Invion | - |
0
|
$0.01 | Buy/Sell | $0.00 | -100.00% |
Bionomics EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Bionomics's EBIT has grown by 915.33%, from $-2.74M to $-27.82M. For the next year, analysts are expecting EBIT to reach $-35.80M – an increase of 28.68%. Over the next seven years, experts predict that EBIT will grow by 56.27%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PTX Stock Forecast | Prescient Therapeutics |
2
|
$0.05 | Buy/Sell | $0.20 | 180.00% | |
| CYP Stock Forecast | Cynata Therapeutics |
0
|
$0.23 | Buy/Sell | $1.24 | 439.13% | |
| 1AI Stock Forecast | Algorae Pharmaceuticals | - |
-4
|
$0.01 | Buy/Sell | $0.00 | -100.00% |
Bionomics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Bionomics's EPS has increased by 100.00%, going from $-2.36 to $0.00. In the next year, analysts are expecting an increase in EPS, predicting it will reach $-4.17 – an increase of 100.00%. The Bionomics forecast is for EPS to reach $-4.86 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IMC Stock Forecast | Immuron | - |
0
|
$0.07 | Buy/Sell | $0.00 | -100.00% |
| ATH Stock Forecast | Alterity Therapeutics | - |
0
|
$0.00 | Buy/Sell | $0.75 | 0.00% |
| GTG Stock Forecast | Genetic Technologies | - |
0
|
$0.12 | Buy/Sell | $1.00 | -100.00% |
.jpg)